AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 222 min read$MEDP

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

Original reporting
finance.yahoo.com
Published Oct 22, 2026, 5:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 22, 2026, 5:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Medpace (MEDP) Q3 2026 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$MEDPBullishHigh
01

Why it matters

Guidance raise could trigger buying pressure; however, margin volatility and upcoming cost increases may temper enthusiasm.

02

Market read

First‑time disclosure of 2026 guidance provides fresh data for traders; likely influences MEDP price action in the near term.

03

What to watch

Higher backlog conversion risk and potential margin pressure from upcoming cost expansion in Cincinnati.

Relevance 8/10Novelty 8/10Timing: post‑earnings release

Background

The transcript details Medpace's Q3 financial results, backlog growth, cash flow, and a new $1B share repurchase authorization.

Company-level read

Ticker impact

$MEDPBullishHigh confidence
Context

Medpace released Q3 2026 earnings with revenue of $716M and raised full-year 2026 revenue guidance to $2.835‑$2.855B and EPS guidance to $17.97‑$18.32.

Expected impact

potential upside as investors price in higher revenue and earnings expectations

Evidence & confidence

Guidance increase of ~1% on revenue and ~3% on EPS exceeds prior consensus, indicating improved performance and may attract buying.

Market effects

Sector

Positive for the CRO/clinical‑trial services sector as Medpace's growth may signal demand strength.

Regional

U.S. biotech services market may see modest uplift.

Global

Limited to investors focused on U.S. healthcare services.

Counterpoint

What could challenge this read

If the guidance lift is modest relative to expectations, the stock may already be priced in, limiting upside.

Key entities

  • Company
    Medpace

    U.S. clinical‑research organization reporting earnings and guidance.

Read at source← All news

StoryMedpace Reports Q3 Earnings Beat and Authorizes $1 Billion Buyback

Also covered by

4 outlets

Related articles

OCT 23
$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

finance.yahoo.com2 min
OCT 22
$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

tradingview.com2 min
OCT 22
$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

finance.yahoo.com2 min
OCT 22
$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.

investing.com2 min
OCT 22
$MEDPHighAI 8/10

Why is Medpace stock sliding today?

Medpace Holdings Inc (MEDP) fell 1.6% in after-hours trading after its Q3 2026 earnings report. Adjusted EPS of $4.84 beat estimates, but full-year revenue guidance of $2.835B-$2.855B missed expectations. The board replaced a $527M stock buyback program with a $1B program. Insiders sold $467M in shares over the past year. The S&P 500, Dow Jones, and NASDAQ also declined during regular trading.

investing.com2 min